Martin Rudwaleit

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Landgrafenstr, 15, 44652 Herne, Germany
    Arthritis Res Ther 10:R104. 2008
  2. ncbi Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis
    M Rudwaleit
    Rheumatology, Department of Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 63:665-70. 2004
  3. ncbi How to diagnose axial spondyloarthritis early
    M Rudwaleit
    Rheumatology, Department of Medicine I, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 63:535-43. 2004
  4. ncbi [Early diagnosis of spondyloarthritis with special attention to the axial forms]
    M Rudwaleit
    Rheumatologie, Medizinische Klinik I, Charite, Universitätsmedizin Berlin Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 64:524-30. 2005
  5. ncbi [Diagnosis and early diagnosis of ankylosing spondylitis]
    M Rudwaleit
    Medizinische Klinik I, Gastroenterologie Infektiologie Rheumatologie, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 63:193-202. 2004
  6. ncbi Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study
    M Rudwaleit
    Charite University Medicine Berlin, Benjamin Franklin Campus, Berlin, Germany
    Ann Rheum Dis 68:696-701. 2009
  7. ncbi [Early diagnosis of ankylosing spondylitis and spondyolarthritis and predictors of outome]
    Martin Rudwaleit
    Rheumatologie, Medizinische Klinik I, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Wien Med Wochenschr 158:186-90. 2008
  8. ncbi MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis
    M Rudwaleit
    Medizinische Klinik I, Campus Benjamin Franklin, Charite Medical School Berlin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 67:1276-81. 2008
  9. ncbi A case of axial undifferentiated spondyloarthritis diagnosis and management
    Martin Rudwaleit
    Rheumatology, Department of Medicine I, Charite Universitatsmedizin, Berlin, Germany
    Nat Clin Pract Rheumatol 3:298-303. 2007
  10. ncbi The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?
    Martin Rudwaleit
    Charite, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 52:1000-8. 2005

Collaborators

Detail Information

Publications105 found, 100 shown here

  1. ncbi The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Landgrafenstr, 15, 44652 Herne, Germany
    Arthritis Res Ther 10:R104. 2008
    ..Whether and how spondylitis and syndesmophyte formation are linked are unclear. Our objective was to investigate whether and how spinal inflammation are associated with new bone formation in ankylosing spondylitis...
  2. ncbi Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis
    M Rudwaleit
    Rheumatology, Department of Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 63:665-70. 2004
    ..TNFalpha blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS)...
  3. ncbi How to diagnose axial spondyloarthritis early
    M Rudwaleit
    Rheumatology, Department of Medicine I, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 63:535-43. 2004
    ..Chronic low back pain (LBP), the leading symptom of ankylosing spondylitis (AS) and undifferentiated axial spondyloarthritis (SpA), precedes the development of radiographic sacroiliitis, sometimes by many years...
  4. ncbi [Early diagnosis of spondyloarthritis with special attention to the axial forms]
    M Rudwaleit
    Rheumatologie, Medizinische Klinik I, Charite, Universitätsmedizin Berlin Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 64:524-30. 2005
    ..New strategies how to make an early diagnosis and how primary care physicians can screen for these patients are discussed...
  5. ncbi [Diagnosis and early diagnosis of ankylosing spondylitis]
    M Rudwaleit
    Medizinische Klinik I, Gastroenterologie Infektiologie Rheumatologie, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 63:193-202. 2004
    ..An early and reliable diagnosis is relevant to both the patient and the physician since an early diagnosis allows the best therapy to be introduced and consequently maintained...
  6. ncbi Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study
    M Rudwaleit
    Charite University Medicine Berlin, Benjamin Franklin Campus, Berlin, Germany
    Ann Rheum Dis 68:696-701. 2009
    ..To evaluate the effect of adalimumab on the frequency of anterior uveitis (AU) flares in patients with active ankylosing spondylitis (AS)...
  7. ncbi [Early diagnosis of ankylosing spondylitis and spondyolarthritis and predictors of outome]
    Martin Rudwaleit
    Rheumatologie, Medizinische Klinik I, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Wien Med Wochenschr 158:186-90. 2008
    ..Male sex, extraspinal manifestations, and existing syndesmophytes on radiographs appear to be predictors of a worse disease outcome...
  8. ncbi MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis
    M Rudwaleit
    Medizinische Klinik I, Campus Benjamin Franklin, Charite Medical School Berlin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 67:1276-81. 2008
    ..To evaluate the role of MRI in predicting a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) improvement of at least 50% (BASDAI 50) upon anti-tumour necrosis factor (TNF) therapy of active ankylosing spondylitis (AS)...
  9. ncbi A case of axial undifferentiated spondyloarthritis diagnosis and management
    Martin Rudwaleit
    Rheumatology, Department of Medicine I, Charite Universitatsmedizin, Berlin, Germany
    Nat Clin Pract Rheumatol 3:298-303. 2007
    ..A 32-year-old white man presented with features of inflammatory back pain, including awakening at night and morning stiffness. He had acute back pain 4 years earlier as a result of a herniated lumbar disc...
  10. ncbi The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?
    Martin Rudwaleit
    Charite, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 52:1000-8. 2005
  11. ncbi Infliximab for the treatment of ankylosing spondylitis
    M Rudwaleit
    Charite Campus Benjamin Franklin, Rheumatology, Department of Medicine I, Hindenburgdamm 30, 12200 Berlin, Germany
    Expert Opin Biol Ther 5:1095-109. 2005
    ..The short-term benefit/risk ratio of infliximab is clearly in favour of the drug, and it is estimated that at present up to 30% of patients with active AS are in need of this kind of effective treatment...
  12. ncbi [Diagnosis and treatment of ankylosing spondylitis (Bechterew disease)]
    M Rudwaleit
    Medizinische Klinik I -- Rheumatologie, , Campus Benjamin Franklin, Berlin
    Dtsch Med Wochenschr 130:1882-6. 2005
  13. ncbi Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria
    Martin Rudwaleit
    Charite, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 54:569-78. 2006
    ..In this exploratory study, we sought to evaluate the individual features of IBP and to compose and compare various combinations of features for use as classification and diagnostic criteria...
  14. ncbi Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion
    Martin Rudwaleit
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin Hospital, Berlin, Germany
    Rheumatology (Oxford) 48:551-7. 2009
    ..To evaluate the effectiveness and safety of adalimumab in treating patients with AS and advanced structural damage...
  15. ncbi Adalimumab improves sleep and sleep quality in patients with active ankylosing spondylitis
    Martin Rudwaleit
    Charite University, Benjamin Franklin Campus, Berlin, Germany
    J Rheumatol 38:79-86. 2011
    ..This subanalysis of the RHAPSODY study (Review of Safety and Effectiveness with Adalimumab in Patients with Active Ankylosing Spondylitis) was conducted to evaluate the effect of adalimumab on sleep in patients with active AS...
  16. ncbi Classification criteria for psoriatic arthritis and ankylosing spondylitis/axial spondyloarthritis
    Martin Rudwaleit
    Department of Medicine, Charite University Medicine, Campus Benjamin Franklin, Berlin, Germany
    Best Pract Res Clin Rheumatol 24:589-604. 2010
    ..Both the CASPAR and the ASAS criteria for axial SpA are likely to be of use as diagnostic criteria...
  17. ncbi Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group
    M Rudwaleit
    Department of Rheumatology, Charite University Medicine, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:1520-7. 2009
    ..Magnetic resonance imaging (MRI) of sacroiliac joints has evolved as the most relevant imaging modality for diagnosis and classification of early axial spondyloarthritis (SpA) including early ankylosing spondylitis...
  18. ncbi The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal
    M Rudwaleit
    Med Klinik I, Charite, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:770-6. 2009
    ..The objective of this study was to develop candidate classification criteria for axial SpA that include patients with but also without radiographic sacroiliitis...
  19. ncbi The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
    M Rudwaleit
    Med Klinik I, Charite, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:777-83. 2009
    ..To validate and refine two sets of candidate criteria for the classification/diagnosis of axial spondyloarthritis (SpA)...
  20. ncbi Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis
    Martin Rudwaleit
    Charite University Medicine Berlin, Campus Benjamin Franklin Hospital, Medical Department I, Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany
    J Rheumatol 36:801-8. 2009
    ..We evaluated the effectiveness and safety of adalimumab in a large cohort of patients with active ankylosing spondylitis (AS) and identified clinical predictors of good clinical response...
  21. ncbi Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis
    Heiner Appel
    , Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 54:2845-51. 2006
    ..The findings of increased numbers of T cells and B cells and neoangiogenesis suggest that these features play a role in the pathogenesis of AS...
  22. ncbi The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort
    Martin Rudwaleit
    Charité Medical University Hospital, Campus Benjamin Franklin, and German Rheumatism Research Centre, Berlin, Germany
    Arthritis Rheum 60:717-27. 2009
    ..Moreover, we sought to identify determinants of the development of radiographic sacroiliitis...
  23. ncbi Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis
    Denis Poddubnyy
    Charite Universitatsmedizin, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 64:1388-98. 2012
    ..To assess prospectively the rates and to explore predictors of spinal radiographic progression over 2 years in a cohort of patients with early axial spondylarthritis (SpA)...
  24. ncbi Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis
    Heiner Appel
    Charite Berlin, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 60:3257-62. 2009
    ..The contribution of osteocytes in regulating local bone remodeling in arthritis is unknown. The aim of this study was to investigate the role of osteocytes as contributors to bone remodeling in ankylosing spondylitis (AS)...
  25. ncbi Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort
    Denis Poddubnyy
    Med Department I, Rheumatology, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Ann Rheum Dis 71:1616-22. 2012
    ..To investigate the influence of non-steroidal anti-inflammatory drugs (NSAIDs) intake on radiographic spinal progression over 2 years in patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (SpA)...
  26. ncbi New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept
    In Ho Song
    Department of Rheumatology, Division of Medicine, and Institute for Pathology Research Center ImmunoSciences RCIS, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    J Rheumatol 35:532-6. 2008
    ..New onset of CD may be considered as an immune-mediated injury induced by etanercept. Although this is an intriguing hypothesis, any causative role of etanercept remains unproven at this stage...
  27. ncbi Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial
    Hildrun Haibel
    Benjamin Franklin Hospital, Berlin, Germany
    Arthritis Rheum 54:678-81. 2006
  28. ncbi Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis
    Denis Poddubnyy
    Department of Rheumatology, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 70:1369-74. 2011
    ..To assess the progression of radiographic sacroiliitis in a cohort of patients with early axial spondyloarthritis over a period of 2 years and to explore predictors of progression...
  29. ncbi Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
    Martin Rudwaleit
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin Hospital, Hindenburgdamm 30, 12200 Berlin, Germany
    Arthritis Res Ther 12:R117. 2010
    ..Our objective was to evaluate the effectiveness and safety of adalimumab, 40 mg every other week, for patients with AS or PsA and prior treatment with infliximab (IFX) and/or etanercept (ETN)...
  30. ncbi In vitro observations of T cell responsiveness to recall antigens during tumor necrosis factor-alpha-blocking therapy in patients with ankylosing spondylitis
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, Charite Berlin, Campus Benjamin Franklin, Hindenbergdamm 30, Berlin, Germany
    J Rheumatol 34:2264-70. 2007
    ..This raises the question if an alteration of T cell function can be detected by in vitro analysis to identify patients who might be more at risk of acquiring such infectious diseases...
  31. ncbi Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
    Martin Rudwaleit
    Charite University Medicine Berlin, Benjamin Franklin Campus, Medical Department I, Rheumatology, Hindenburgdamm 30, 12203 Berlin, Germany
    Arthritis Res Ther 12:R43. 2010
    ..The purpose of this study was to investigate the effectiveness of adalimumab in enthesitis and peripheral arthritis in patients with ankylosing spondylitis (AS)...
  32. ncbi Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two
    Hildrun Haibel
    Charité Medical University Hospital, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 58:1981-91. 2008
    ..To evaluate the efficacy and safety of the tumor necrosis factor (TNF) antagonist adalimumab in patients with axial spondylarthritis (SpA) without radiographically defined sacroiliitis refractory to conventional treatment...
  33. ncbi Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group
    Kay Geert A Hermann
    Department of Radiology, Charite University Hospital, Berlin, Germany
    Ann Rheum Dis 71:1278-88. 2012
    ..The aim of this study was to define characteristic MRI findings in the spine of patients with axial spondyloarthritis (SpA) and provide a definition of a positive spinal MRI for inflammation and structural changes...
  34. ncbi Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care
    Denis Poddubnyy
    Department of Rheumatology, Charite Campus Benjamin Franklin, Berlin, Germany
    J Rheumatol 38:2452-60. 2011
    ..To evaluate 2 referral strategies for axial spondyloarthritis (SpA) in patients with chronic low back pain at the primary care level...
  35. ncbi Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes
    Joachim Sieper
    , Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 58:649-56. 2008
  36. ncbi Diagnosing early ankylosing spondylitis
    In Ho Song
    Rheumatology, Department of Medicine, Charité Medical University Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Curr Rheumatol Rep 9:367-74. 2007
    ..Finally, referral strategies for patients seen by primary care physicians seem to work well and are currently under further valuation...
  37. ncbi Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept
    M Rudwaleit
    Rheumatology, , Berlin, Germany
    Ann Rheum Dis 64:1305-10. 2005
    ..The potential role of etanercept on deceleration of chronic spinal changes needs further study...
  38. ncbi Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial
    In Ho Song
    Department of Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 71:1212-5. 2012
    ....
  39. ncbi Relation of HLA-B27, tumor necrosis factor-α promoter gene polymorphisms, and T cell cytokine production in ankylosing spondylitis -- a comprehensive genotype-phenotype analysis from an observational cohort
    Denis A Poddubnyy
    Department of Rheumatology, Evangelische Krankenhaus Hagen Haspe, Germany
    J Rheumatol 38:2436-41. 2011
    ..The objective of our study was to assess these associations in a different cohort of patients with ankylosing spondylitis (AS) and to evaluate any effect on clinical measurements...
  40. ncbi Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, Charite Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Arthritis Res Ther 10:R125. 2008
    ..Therefore, we analysed parameters of cartilage degradation, neoangiogenesis, and new bone formation in different cohorts of patients with axial spondyloarthritis with and without treatment with TNF-alpha blocker agents...
  41. ncbi Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis
    Heiner Appel
    , Campus Benjamin Franklin, Department of Gastroenterology, Infectiology and Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany
    Arthritis Res Ther 8:R143. 2006
    ..This first study correlating histopathological changes in the spine of patients with AS with findings in MRI scans suggests that a substantial degree of bone marrow inflammation and edema is necessary to be detected by MRI...
  42. ncbi Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis
    Henning Christian Brandt
    Rheumatology, Department of Medicine I, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 66:1479-84. 2007
    ..Referral parameters that are easy for doctors in primary care to apply to patients presenting with possible AS could contribute to earlier diagnosis...
  43. ncbi Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus
    Robert Biesen
    Charite Universitatsmedizin Berlin, Humboldt University of Berlin, Germany
    Arthritis Rheum 58:1136-45. 2008
    ..This study was undertaken to establish a feasible biomarker for IFN effects with respect to disease activity and effectiveness of IFN-suppressive therapy in SLE patients...
  44. ncbi Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis
    J Brandt
    Benjamin Franklin Hospital, Free University Berlin, Berlin, Germany
    Arthritis Rheum 48:1667-75. 2003
    ..Thus, it seems probable that etanercept must be administered continuously in most AS patients to achieve permanent inhibition of the inflammatory process...
  45. ncbi Limited diagnostic value of unilateral sacroiliitis in scintigraphy in assessing axial spondyloarthritis
    In Ho Song
    Charité Medical University, Campus Benjamin Franklin, Medical Clinic I, Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany
    J Rheumatol 37:1200-2. 2010
    ..To assess the diagnostic value for axial spondyloarthritis (SpA) of unilateral sacroiliitis in scintigraphy in daily clinical practice...
  46. ncbi Early spondyloarthritis
    Denis Poddubnyy
    Rheumatology, Medical Department I, Campus Benjamin Franklin, Charite Universitatsmedizin Berlin, Hindenburgdamm 30, Berlin 12203, Germany
    Rheum Dis Clin North Am 38:387-403. 2012
    ..This article discusses the current concept of the disease, typical manifestations, advances in diagnosis, and current treatment recommendations...
  47. ncbi The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic
    Denis Poddubnyy
    Correspondence to Dr Denis Poddubnyy, Rheumatology, Medical Department I, Campus Benjamin Franklin, Charite Universitatsmedizin Berlin, Hindenburgdamm 30, Berlin 12203, Germany
    Ann Rheum Dis 71:1998-2001. 2012
    ....
  48. ncbi High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis
    Gisela Ruiz Heiland
    Department of Internal Medicine III, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 71:572-4. 2012
    ..The molecular mechanisms of syndesmophyte formation in ankylosing spondylitis (AS) are yet to be characterised. Molecules involved in bone formation such as Wnt proteins and their antagonists probably drive syndesmophyte formation in AS...
  49. ncbi Congenital absence of the portal vein with splenomegaly and hypersplenism in a young woman
    Heiner Appel
    Department of Gastroenterology and Rheumatology, University Hospital Benjamin Franklin, Berlin, Germany
    Digestion 67:105-10. 2003
    ..A CT scan revealed an empty liver hilus without portal vein. Here we discuss clinical aspects of this patient, show radiologic and histopathologic findings, and compare them to other cases in the literature...
  50. ncbi Adalimumab for the treatment of ankylosing spondylitis
    Joachim Sieper
    Campus Benjamin Franklin, Rheumatology, Medical Department I, Charite, Hindenburgdamm 30, 12200 Berlin, Germany
    Expert Opin Pharmacother 8:831-8. 2007
    ..In open and placebo-controlled trials, the drug was shown to be safe and effective in ankylosing spondylitis patients. Long-term treatment data of up to 2 years are now available, confirming efficacy and acceptable safety...
  51. ncbi From transcriptome to cytome: integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseases
    Marta Steinbrich-Zöllner
    German Arthritis Research Center DRFZ, Immune Monitoring Core, Berlin, Germany
    Cytometry A 73:333-40. 2008
    ..The integration of an appropriate bioinformatic solution as presented here by the combination of a custom-made Access database along with cluster- and prediction-analysis tools predestine our approach to promote the human cytome project...
  52. ncbi [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]
    J Brandt
    Klinikum Benjamin Franklin, Medizinische Klinik I, Rheumatologie, Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 62:264-73. 2003
    ..The purpose of this study was the validation of a German translation of the Bath Ankylosing Spondylitis Index (BASDAI)...
  53. ncbi Whole-body magnetic resonance imaging evaluation of widespread inflammatory lesions in a patient with ankylosing spondylitis before and after 1 year of treatment with infliximab
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, , Campus Benjamin Franklin, Berlin, Germany
    J Rheumatol 34:2497-8. 2007
  54. ncbi An elevated level of IL-10- and TGFbeta-secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis
    Heiner Appel
    Department of Rheumatology, Charite Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Germany
    Clin Rheumatol 23:435-40. 2004
    ..Whether this is due to a more general difference in TNF-alpha, IL-10 or TGF-beta production which is genetically determined or regulated by T cells remains to be determined...
  55. ncbi Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab
    Jianxiang Zou
    Benjamin Franklin Klinikum, Deutsches Rheumaforschungszentrum, Berlin, Germany
    Arthritis Rheum 48:780-90. 2003
    ..This is likely to be a relevant mechanism for the clinical efficacy of this therapy...
  56. ncbi Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis
    J Brandt
    Department of Gastroenterology/Rheumatology, Charit, Berlin, Germany
    Ann Rheum Dis 63:1438-44. 2004
    ..The ASAS 40% improvement criterion has the advantage of setting a high threshold, but only in patient reported outcomes. The choice between these improvement criteria needs to be based on further validation from upcoming trials...
  57. ncbi Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab
    J Sieper
    Department of Rheumatology, , Campus Benjamin Franklin, Berlin, Germany
    Rheumatology (Oxford) 44:1525-30. 2005
    ..Disease activity parameters did not directly correlate with MRI, but both pointed in the same direction. Both types of information may be useful for the definition of response to anti-TNF therapy...
  58. ncbi Ankylosing spondylitis: an overview
    J Sieper
    Department of Gastroenterology and Rheumatology, UKBF, Free University, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 61:iii8-18. 2002
    ..Emerging biological therapies target the inflammatory processes underlying AS, and thus, may favourably alter the disease process, in addition to providing symptom relief...
  59. ncbi Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept
    J Zou
    Rheumatology, Benjamin Franklin Klinikum, Deutsches Rheumaforschungszentrum, Berlin, Germany
    Ann Rheum Dis 62:561-4. 2003
    ..CONCLUSIONS: Neutralisation of peripheral TNFalpha does not induce a down regulation of the ability of T cells to produce TNFalpha but rather an up regulation, possibly due to a counterregulatory mechanism...
  60. ncbi Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis
    J Listing
    Deutsches Rheuma ForschungsZentrum, Berlin, Germany
    Ann Rheum Dis 63:1670-2. 2004
    ..To analyse the impact of infliximab treatment on the number of hospital inpatient days and days of sick leave in patients with active ankylosing spondylitis (AS)...
  61. ncbi The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research
    I H Song
    Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 67:1535-40. 2008
    ..The diagnostic value of scintigraphy in detecting sacroiliitis in patients with spondyloarthritis is not clear...
  62. ncbi New approaches to diagnosis and classification of axial and peripheral spondyloarthritis
    Martin Rudwaleit
    Charite University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany
    Curr Opin Rheumatol 22:375-80. 2010
    ..The diagnostic delay in AS of several years is mainly attributable to the late appearance of definite sacroiliitis on radiographs. Efforts have been made in recent years to improve and standardize making an early diagnosis...
  63. ncbi Concepts and epidemiology of spondyloarthritis
    Joachim Sieper
    Department of Medicine, Rheumatology, Charite, University Medicine Berlin, Germany
    Best Pract Res Clin Rheumatol 20:401-17. 2006
    ..Incidence rates of 0.5-8.2/100 000 population and prevalence rates of 0.2-1.2% have been described for AS, and about double these figures have been reported for SpA...
  64. ncbi Adalimumab for the treatment of psoriatic arthritis
    Denis A Poddubnyy
    Rheumatology, Medical Department I, , Hindenburgdamm 30, 12203 Berlin, Germany
    Expert Rev Clin Immunol 5:671-81. 2009
    ..The response of joints and skin and quality of life improvement was sustained over 2 years of therapy. In addition, adalimumab suppressed structural joint damage and retards radiographic progression of PsA...
  65. ncbi Coronary vasospasm-induced acute diastolic dysfunction in a patient with Raynaud's phenomenon
    Carsten Tschope
    Charite University Medicine Berlin, Campus Benjamin Franklin, Department of Cardiology and Pneumology, Hindenburgdamm 30, 12200, Berlin, Germany
    Clin Res Cardiol 95:344-8. 2006
    ..Thus, episodes of dyspnea in patients with Raynaud's phenomenon might be also interpreted as a coronary ischemia equivalent, which may belong to a visceral form of Raynaud's phenomenon and which are sensitive to iloprost infusions...
  66. ncbi Six months open label trial of leflunomide in active ankylosing spondylitis
    H Haibel
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 64:124-6. 2005
    ..To examine the potential therapeutic effects of leflunomide in patients with active AS in an open label study...
  67. ncbi The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
    J Sieper
    Rheumatology, Medizinische Klinik I, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 68:ii1-44. 2009
    ..The focus of this handbook is on practicality, with many examples of MRI and x ray images, which will help to standardise not only patient care but also the design of clinical studies...
  68. ncbi Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial
    I H Song
    Campus Benjamin Franklin, Med Clinic I, Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 70:590-6. 2011
    ..To evaluate the potential of etanercept versus sulfasalazine to reduce active inflammatory lesions on whole-body MRI in active axial spondyloarthritis with a symptom duration of less than 5 years...
  69. ncbi Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis
    D A Poddubnyy
    Department of Rheumatology, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Ann Rheum Dis 69:1338-41. 2010
    ....
  70. ncbi New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)
    J Sieper
    Medizinische Klinik I, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:784-8. 2009
    ..In the present report, a new approach for the development of IBP classification criteria is discussed...
  71. ncbi Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations
    I H Song
    Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:1701-7. 2009
    ....
  72. ncbi [Diagnosis of reactive arthritis]
    H Haibel
    Charite, Universitatsmedizin Berlin, Campus Benjamin Franklin, Abt f Rheumatologie, Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 63:211-5. 2004
    ..To assess the clinical value of a test, it is not only necessary to know the specificity and sensitivity of a test but also the assumed likelihood of the disease (pretest probability)...
  73. ncbi [Fever of unknown origin in the 21st century. 2. Non-infectious diseases (autoimmune diseases)]
    T Schneider
    Medizinische Klinik 1 (Gastroenterologie, Infektiologie und Rheumatologie, , Campus Benjamin Franklin, Berlin
    Dtsch Med Wochenschr 130:2774-8. 2005
  74. ncbi [Outcome parameters in ankylosing spondylitis]
    H Haibel
    Z Rheumatol 65:131-4, 136-8. 2006
    ..However, it could also be shown that conventional disease modifying antirheumatic drugs (DMARDs) are not effective in the treatment of the axial forms of SpA...
  75. ncbi Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study
    J Sieper
    Benjamin Franklin University Berlin, Berlin, Germany
    Ann Rheum Dis 67:323-9. 2008
    ..To demonstrate the non-inferiority of celecoxib compared with diclofenac in subjects with ankylosing spondylitis (AS)...
  76. ncbi Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
    J Brandt
    Department of Gastroenterology/Rheumatology, Charit, Medical University Berlin, Campus Benjamin Franklin, Germany
    Rheumatology (Oxford) 44:342-8. 2005
    ..CONCLUSIONS: This study shows that treatment with etanercept is efficacious and safe after readministration over 1 yr in patients with active AS not taking DMARDs or steroids...
  77. ncbi How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
    J Sieper
    Medical Department, Rheumatology, Campus Benjamin Franklin, Charite, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 64:iv61-4. 2005
    ....
  78. ncbi Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care
    J Sieper
    Medical Department I, Rheumatology, Charite, University Medicine Berlin, Germany
    Ann Rheum Dis 64:659-63. 2005
    ..Primary care physicians need easy to apply parameters to help them identify patients with suspected AS for onward referral. The best measures found were inflammatory back pain and HLA-B27 positivity...
  79. ncbi [Fever of unknown origin in the 21st century: infectious diseases]
    T Schneider
    Medizinische Klinik 1 Gastroenterologie, Infektiologie und Rheumatologie, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin
    Dtsch Med Wochenschr 130:2708-12. 2005
    ..Therefore and because of economic reasons patients with FUO should be investigated in specialized centres with a department for rheumatology and infectious diseases...
  80. ncbi Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice
    H Haibel
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin Hospital, Berlin, Germany
    Clin Exp Rheumatol 26:247-52. 2008
    ..The aim of this study was to prospectively investigate the therapeutic efficacy and safety of infliximab therapy in NSAID-refractory AS patients, with special emphasis on impact on quality of life in daily practice...
  81. ncbi No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial
    H Haibel
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 66:419-21. 2007
    ..To examine the potential therapeutic effect of methotrexate 20 mg given weekly as subcutaneous injections to 20 patients with ankylosing spondylitis refractory to non-steroidal antirheumatic drugs...
  82. ncbi Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis
    Heiner Appel
    Department of Medicine at the Charité Hospital Benjamin Franklin, Berlin, Germany
    Nat Clin Pract Rheumatol 4:578-9. 2008
    ..In this Viewpoint the authors explore the relevance of osteoproliferation amongst other outcome parameters...
  83. ncbi Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial
    I H Song
    Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 62:1290-7. 2010
    ....
  84. ncbi Low incidence of reactive arthritis in children following a salmonella outbreak
    M Rudwaleit
    Section of Rheumatology, Department of Medicine, University Hospital Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 60:1055-7. 2001
    ..To assess the incidence of reactive arthritis (ReA) in an outbreak of salmonella infection in a large cohort of children in Germany...
  85. ncbi CD27+ memory and CD27- effector CD8+ T cells are responsible for a decreased production of proinflammatory cytokines in HLA B27-positive subjects
    S Kohler
    Campus Benjamin Franklin, Charite Berlin, Germany
    Clin Exp Rheumatol 23:840-6. 2005
    ..The aim of this study was to identify CD4+ and CD8+ T cell subsets responsible for the observed lower cytokine secretion capacity in HLA B27-positives...
  86. ncbi Massive splenomegaly and hypersplenism in a young woman with primary Sjögren's syndrome
    Heiner Appel
    Department of Gastroenterology and Rheumatology, Benjamin Franklin Medical Center, Berlin, Germany
    J Rheumatol 29:2012-3. 2002
  87. ncbi Atopic disorders in ankylosing spondylitis and rheumatoid arthritis
    M Rudwaleit
    Rheumatology, University Hospital Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 61:968-74. 2002
    ..It may further indicate that the cytokine deviation towards an impaired Th1 pattern in AS is less strong than the cytokine deviation towards Th1 in RA, a finding which may affect future therapeutic approaches...
  88. ncbi Ankylosing spondylitis and bowel disease
    Martin Rudwaleit
    Rheumatology, Charite-Campus Benjamin Franklin, Berlin, Germany
    Best Pract Res Clin Rheumatol 20:451-71. 2006
    ..Adalimumab appears to be effective in treating both AS and IBD; however, official approval is pending. Currently, infliximab is the drug of choice for the treatment of patients with active AS associated with IBD...
  89. ncbi Cytokine gene polymorphisms relevant for the spondyloarthropathies
    M Rudwaleit
    Medizinische Klinik I, , Berlin, Germany
    Curr Opin Rheumatol 13:250-4. 2001
    ..Here we review the evidences for association of TNF-alpha and IL-10 polymorphisms with spondyloarthropathies and their functional implications...
  90. ncbi Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis
    J Zou
    Department of Gastroenterology and Rheumatology, , Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 64:722-9. 2005
    ..CONCLUSION: A G1 peptide-specific CD8+ T cell response is present in AS but also in patients with RA. It does not seem to be HLA-B27 restricted. Whether such a response has a role in the pathogenesis of AS needs clarification...
  91. ncbi Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
    H Haibel
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 64:296-8. 2005
    ..To examine the therapeutic effect of the interleukin 1 (IL1) receptor antagonist anakinra in ankylosing spondylitis in an open label trial...
  92. ncbi Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs
    I H Song
    , Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 58:929-38. 2008
  93. ncbi Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis
    J Zou
    Department of Rheumatology, Klinikum Benjamin Franklin, Free University, Berlin, Germany
    Rheumatology (Oxford) 42:846-55. 2003
    ..G1-immunodominant epitopes were identified. The relevance of this finding for the pathogenesis of AS and RA remains to be established...
  94. ncbi Co-occurrence of spondyloarthropathy and connective tissue disease: development of Sjögren's syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitis
    J Brandt
    Medical Department I, Rheumatology, Benjamin Franklin Hospital, Free University of Berlin, Germany
    Clin Exp Rheumatol 20:80-4. 2002
    ..We describe the rare development of MCTD in an AS patient and report, for the first time, the onset of MCTD potentially triggered by sulfasalazine...
  95. ncbi Association of genotypes affecting the expression of interleukin-1beta or interleukin-1 receptor antagonist with osteoarthritis
    V Moos
    Deutsches Rheuma Forschungs Zentrum, and Klinikum Benjamin Franklin, Free University, Berlin, Germany
    Arthritis Rheum 43:2417-22. 2000
    ..To establish a hierarchy among the cytokines and growth factors expressed in articular chondrocytes, this study investigated cytokine genes for known polymorphisms that may contribute to the deregulated expression in OA cartilage...
  96. ncbi Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept
    Jan Brandt
    Department of Gastroenterology Rheumatology, Benjamin Franklin Hospital, Free University FU Berlin, Germany
    J Rheumatol 31:531-8. 2004
    ..In this open study we examined the efficacy of the TNF-alpha receptor fusion protein etanercept in patients with uSpA...
  97. ncbi Biologic therapies in the spondyloarthritis: new opportunities, new challenges
    Juergen Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Curr Opin Rheumatol 15:394-407. 2003
    ..These can be largely prevented by appropriate screening. At it stands now, the benefits of antitumor necrosis factor therapy in ankylosing spondylitis seem to outweigh these shortcomings...
  98. ncbi Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment
    Robert B M Landewe
    Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, University Maastricht, 6202 AZ Maastricht, The Netherlands
    J Rheumatol 32:2050-5. 2005
    ....
  99. ncbi Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment
    Cédric Lukas
    Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, The Netherlands
    J Rheumatol 34:862-70. 2007
    ..We investigated feasibility, inter-reader reliability, sensitivity to change, and discriminatory ability of 3 different scoring methods for MRI activity and change in activity of the spine in patients with AS...
  100. ncbi Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet, Herne Ruhr University, Bochum, Germany
    J Rheumatol 34:510-5. 2007
    ....
  101. ncbi Application of the OMERACT filter to scoring methods for magnetic resonance imaging of the sacroiliac joints and the spine. Recommendations for a research agenda at OMERACT 7
    Desiree M F M Van der Heijde
    Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, University Maastricht, 6202 AZ Maastricht, The Netherlands
    J Rheumatol 32:2042-7. 2005
    ..Research on assessing structural damage was considered less important. The specific process and results of this initiative are discussed...